Treatment of cancer with GM-CSF antagonists
By using GM-CSF antagonists to inhibit the immunosuppressive activity of MDSCs, combined with ICI, the problem of tumor cell immunosuppression was solved, and the therapeutic effect on immune checkpoint inhibitor-resistant cancers was enhanced.
Patent Information
- Application Number
- CN202410532037.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-06-03
- Filing Date
- 2020-06-03
- Publication Date
- 2024-11-15
AI Technical Summary
Tumor cells induce PD-L1 by expressing GM-CSF, leading to immunosuppression. This results in limited response of immunotherapy to tumor cells, making it difficult to effectively treat immune checkpoint inhibitor-resistant or cancer-resistant cancers.
Using GM-CSF antagonists to suppress the immunosuppressive activity of bone marrow-derived suppressor cells (MDSCs), combined with immune checkpoint inhibitors (ICIs), to block the PD-L1 signaling pathway and enhance the immune response.
Lowering PD-L1 levels enhances T-cell responses, improves the effectiveness of immunotherapy, and contributes to the treatment of anti-cancer diseases.
Smart Images

Figure BDA0004818365160000291 
Figure HDA0004818365170000011 
Figure HDA0004818365170000021
Abstract
Description
[0001] This application is a divisional application of the Chinese invention patent application with application date of June 3, 2020, application number: 202080054412.7, and invention name: “Treating cancer with GM-CSF antagonists”.
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS
[0003] This application claims priority to U.S. Provisional Patent Application No. 62 / 856,638, filed on June 3, 2019, which is incorporated herein by reference in its entirety for all purposes.
[0004] Sequence Listing
[0005] This specification refers to the sequence listing (submitted electronically on June 3, 2020 in the form of a .txt file named "KPL-035WO_SL.txt"). The .txt file was generated on June 3, 2020 and is 4KB in size. The entire contents of the sequence listing are incorporated herein by reference. Technical Field Background Art
[0006] Tumor cells express unique antigens that may be recognized by the host T cell repertoire and serve as potent targets for tumor immunotherapy. However, tumor cells evade host immunity and express inhibitory cytokines that suppress the natural antigen presenting effector cell population. One element of this immunosuppressive environment is the increased presence of regulatory T cells found in the tumor bed, draining lymph nodes, and circulation of patients with malignant tumors. One area of further research is the development of therapeutic agents that reverse tumor-associated anergy and stimulate effector cells to recognize and eliminate malignant cells. Summary of the invention
[0007] The present invention provides, inter alia, an improved method for treating cancer using GM-CSF antagonists based on the inhibition of the immunosuppressive activity of myeloid-derived suppressor cells. The present invention is based in part on the unexpected discovery that GM-CSF induces the expression of PD-L1 on MDSCs with immunosuppressive activity, and that this expression can be inhibited by antagonizing GM-CSF. The present invention also provides methods for treating cancer using GM-CSF antagonists in combination with other cancer therapies as further described herein.
[0008] In some aspects, the invention provides a method of treating cancer comprising administering a GM-CSF antagonist to a patient in need of treatment, wherein administration of the GM-CSF antagonist results in suppression of the immunosuppressive activity of myeloid-derived suppressor cells (MDSCs).
[0009] In some aspects, the invention provides a method of inhibiting the immunosuppressive activity of myeloid-derived suppressor cells (MDSCs) in a patient suffering from cancer, comprising administering a GM-CSF antagonist to the patient.
[0010] In some aspects, the invention provides a method of enhancing an immune response to a cancer treatment, comprising administering a GM-CSF antagonist to a patient receiving cancer treatment, wherein the immune response is increased compared to a control.
[0011] In some embodiments, the immune response is the percentage of T cell proliferation. In some embodiments, the T cell is CD8 positive (CD8+). In some embodiments, the T cell is CD4 positive (CD4+). In some embodiments, the T cell is double positive for CD8 and CD4 (CD8+ / CD4+).
[0012] In some embodiments, the control indicates the level of immune response in the patient prior to administration of the GM-CSF antagonist. In some embodiments, the control is a reference immune response level in a control patient receiving cancer treatment without the GM-CSF antagonist or a reference immune response level based on historical data.
[0013] In some embodiments, the cancer therapy is immunotherapy.
[0014] In some embodiments, administration of a GM-CSF antagonist increases the efficacy of immunotherapy.
[0015] In one aspect, the invention provides, inter alia, a method of inhibiting PD-L1 in a cancer patient compared to a control, comprising administering a GM-CSF antagonist to a patient in need of treatment.
[0016] In some embodiments, administration of a GM-CSF antagonist reduces PD-L1 levels in a cancer patient.
[0017] In some embodiments, the control is indicative of the level of PD-L1 in the patient prior to administration of the GM-CSF antagonist.
[0018] In some embodiments, the control is a reference PD-L1 level in a control patient receiving cancer treatment without a GM-CSF antagonist or a reference PD-L1 level based on historical data.
[0019] In some embodiments, the PD-L1 level in the patient is reduced by at least 10% compared to the control. In some embodiments, the PD-L1 level in the patient is reduced by at least 15% compared to the control. In some embodiments, the PD-L1 level in the patient is reduced by at least 20% compared to the control. In some embodiments, the PD-L1 level in the patient is reduced by at least 30% compared to the control. In some embodiments, the PD-L1 level in the patient is reduced by at least 40% compared to the control. In some embodiments, the PD-L1 level in the patient is reduced by at least 45% compared to the control. In some embodiments, the PD-L1 level in the patient is reduced by at least 50% compared to the control. In some embodiments, the PD-L1 level in the patient is reduced by at least 60% compared to the control. In some embodiments, the PD-L1 level in the patient is reduced by at least 70% compared to the control. In some embodiments, the PD-L1 level in the patient is reduced by at least 75% compared to the control. In some embodiments, the PD-L1 level in the patient is reduced by at least 80% compared to the control. In some embodiments, the PD-L1 level in the patient is reduced by at least 85% compared to the control. In some embodiments, the PD-L1 level in the patient is reduced by at least 90% compared to the control.
[0020] In some embodiments, PD-L1 is expressed on MDSCs. In some embodiments, PD-L1 is expressed on circulating MDSCs. In some embodiments, PD-L1 is expressed on plasma-derived MDSCs. In some embodiments, PD-L1 is expressed on tumor cells. In some embodiments, PD-L1 is expressed on tumor-infiltrating immune cells.
[0021] In some embodiments, the patient has circulating myeloid-derived suppressor cells (MDSCs).
[0022] In some embodiments, the patient suffers from a cancer with low levels of infiltrating T cells.
[0023] In some embodiments, the patient suffers from a cancer that is refractory to an immune checkpoint inhibitor (ICI).
[0024] In some embodiments, the patient suffers from advanced or metastatic cancer.
[0025] In some embodiments, the patient suffers from a cancer selected from the group consisting of breast cancer, colorectal cancer (CRC), prostate cancer, melanoma, bladder cancer, pancreatic cancer, pancreatic ductal adenocarcinoma, hepatocellular carcinoma, gastric cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinoma, non-Hodgkin lymphoma, cervical cancer, gastrointestinal cancer, genitourinary cancer, brain cancer, mesothelioma, renal cell carcinoma, gynecological cancer, ovarian cancer, endometrial cancer, lung cancer, gastrointestinal cancer, pancreatic cancer, esophageal cancer, hepatocellular carcinoma, cholangiocarcinoma, brain cancer, mesothelioma, malignant melanoma, Merkel Cell Carcinoma, multiple myeloma, acute myelogenous leukemia, chronic myelogenous leukemia, myelodysplastic syndrome, or acute lymphocytic leukemia.
[0026] In some embodiments, the patient suffers from a cancer selected from stage IV breast cancer, stage IV colorectal cancer (CRC), prostate cancer, or melanoma.
[0027] The method of any one of the preceding claims, wherein the method further comprises administering to the patient at least one other cancer therapy.
[0028] In some embodiments, the at least one other cancer therapy is chemotherapy, MDSC-targeted therapy, immunotherapy, radiation therapy, and combinations thereof.
[0029] In some embodiments, the GM-CSF antagonist and another cancer therapy are administered concurrently.
[0030] In some embodiments, the GM-CSF antagonist and another cancer therapy are administered sequentially.
[0031] In some embodiments, the patient has been treated with another cancer therapy prior to administration of the GM-CSF antagonist.
[0032] In some embodiments, the patient has received treatment with a GM-CSF antagonist prior to administration of another cancer therapy.
[0033] In some embodiments, the other cancer therapy is an ICI.
[0034] In some embodiments, the ICI antagonizes the activity of PD-1, CTLA-4, B7, BTLA, HVEM, TIM-3, GAL-9, LAG3, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK1, CHK2, or A2aR.
[0035] In some embodiments, the ICI is selected from an anti-PD-1 antibody (optionally pembrolizumab, nivolumab, cemiplimab), an anti-PD-L1 antibody (optionally atezolizumab, avelumab, durvalumab), an anti-CTLA-4 antibody (optionally ipilimumab), an anti-PD-L2 antibody, an anti-B7-H3 antibody, an anti-B7-H4 antibody, an anti-BTLA antibody, an anti-HVEM antibody, an anti-TIM-3 antibody, an anti-GAL-9 antibody, an anti-LAG3 antibody, an anti-VISTA antibody, an anti-KIR antibody, an anti-2B4 antibody, an anti-CD160 antibody, an anti-CGEN-15049 antibody, an anti-CHK1 antibody, an anti-CHK2 antibody, an anti-A2aR antibody, an anti-B-7 antibody, and a combination thereof.
[0036] In some embodiments, the ICI is an anti-PD-L1 antibody. In some embodiments, the ICI is an anti-PD-L1 antibody.
[0037] In some embodiments, the method further comprises administering a chemotherapeutic agent to the patient.
[0038] In some embodiments, the MDSC-targeting therapy is selected from anti-CFS-1R antibody, anti-IL-6 antibody, all-trans retinoic acid, axitinib, entinostat, gemcitabine or phenformin, and combinations thereof.
[0039] In some embodiments, the immunotherapy is selected from a monoclonal antibody, a cytokine, a cancer vaccine, a T cell engagement therapy, and a combination thereof.
[0040] In some embodiments, the monoclonal antibody is selected from an anti-CD3 antibody, an anti-CD52 antibody, an anti-PD1 antibody, an anti-PD-L1 antibody, an anti-CTLA4 antibody, an anti-CD20 antibody, an anti-BCMA antibody, a bispecific antibody or a bispecific T cell engager (BiTE) antibody, and combinations thereof.
[0041] In some embodiments, the cytokine is selected from IFNa, IFNp, IFNy, IFN, IL-2, IL-7, IL-15, IL-21, IL-11, IL-12, IL-18, hGM-CSF, TNFa, or any combination thereof.
[0042] In some embodiments, the GM-CSF antagonist is an anti-GM-CSF antibody or fragment thereof.
[0043] In some embodiments, the GM-CSF antagonist is a soluble GM-CSF receptor.
[0044] In some embodiments, the GM-CSF antagonist is an anti-GM-CSF receptor antibody or a fragment thereof.
[0045] In some embodiments, the anti-GM-CSF receptor antibody or fragment thereof is an anti-GM-CSFRα antibody or fragment thereof.
[0046] In some embodiments, the anti-GM-CSFRα antibody or fragment thereof is a monoclonal antibody specific for human GM-CSFRα.
[0047] In some embodiments, the anti-GM-CSFRα antibody is a human or humanized IgG4 antibody.
[0048] In some embodiments, the anti-GM-CSFRα antibody is mavrilimumab.
[0049] In some embodiments of the present invention, the anti-GM-CSFRα antibody fragment thereof comprises a light chain complementary determining region 1 (LCDR1) defined by SEQ ID NO:6, a light chain complementary determining region 2 (LCDR2) defined by SEQ ID NO:7, and a light chain complementary determining region 3 (LCDR3) defined by SEQ ID NO:8; and a heavy chain complementary determining region 1 (HCDR1) defined by SEQ ID NO:3, a heavy chain complementary determining region 2 (HCDR2) defined by SEQ ID NO:4, and a heavy chain complementary determining region 3 (HCDR3) defined by SEQ ID NO:5.
[0050] In some embodiments, administration of a GM-CSF antagonist and / or an ICI results in a decrease in MDSC levels in a patient compared to a control.
[0051] In some embodiments, administration of a GM-CSF antagonist and / or an ICI results in a reduction in the level of MDSC-mediated immunosuppressive activity in the patient compared to a control.
[0052] In some embodiments, administration of a GM-CSF antagonist and / or an ICI results in a decrease in the percentage of Lin-CD14+HLA-DR-M-MDSCs in the peripheral blood of a patient compared to a control.
[0053] In some embodiments, administration of a GM-CSF antagonist and / or an ICI results in an increase in the percentage of mature MDSC cells in the patient compared to a control.
[0054] In some embodiments, administration of a GM-CSF antagonist and / or an ICI results in a decrease in the level of Treg cells, macrophages, and / or neutrophils compared to a control.
[0055] In some embodiments, administration of a GM-CSF antagonist and / or an ICI results in decreased levels of inhibitory cytokines.
[0056] In some embodiments, the inhibitory cytokine is selected from IL-10 and TGFβ.
[0057] In some embodiments, administration of a GM-CSF antagonist and / or an ICI results in a decrease in the levels of immunosuppressive factors.
[0058] In some embodiments, the immunosuppressive factor is selected from arginase 1, inducible nitric oxide synthase (iNOS), peroxynitrite, nitric oxide, reactive oxygen species, tumor-associated macrophages, and combinations thereof.
[0059] In some embodiments, administration of a GM-CSF antagonist and / or an ICI results in increased levels of CD4+ T effector cells compared to a control.
[0060] In some embodiments, the control is a pre-treatment level or percentage in a patient, or a reference level or percentage based on historical data.
[0061] In some aspects, the present invention provides a pharmaceutical composition for treating cancer, comprising a GM-CSF antagonist and an ICI.
[0062] In some embodiments, the GM-CSF antagonist is an anti-GM-CSF antibody or fragment thereof.
[0063] In some embodiments, the GM-CSF antagonist is a soluble GM-CSF receptor.
[0064] In some embodiments, the GM-CSF antagonist is an anti-GM-CSF receptor antibody or a fragment thereof.
[0065] In some embodiments, the anti-GM-CSF receptor antibody or fragment thereof is an anti-GM-CSFRα antibody or fragment thereof.
[0066] In some embodiments, the anti-GM-CSFRα antibody or fragment thereof is a monoclonal antibody specific for human GM-CSFRα.
[0067] In some embodiments, the anti-GM-CSFRα antibody is a human or humanized IgG4 antibody.
[0068] In some embodiments, the anti-GM-CSFRα antibody is Maverickumab.
[0069] In some embodiments, the anti-GM-CSFRα antibody fragment thereof comprises a light chain complementary determining region 1 (LCDR1) defined by SEQ ID NO:6, a light chain complementary determining region 2 (LCDR2) defined by SEQ ID NO:7, and a light chain complementary determining region 3 (LCDR3) defined by SEQ ID NO:8; and a heavy chain complementary determining region 1 (HCDR1) defined by SEQ ID NO:3, a heavy chain complementary determining region 2 (HCDR2) defined by SEQ ID NO:4, and a heavy chain complementary determining region 3 (HCDR3) defined by SEQ ID NO:5.
[0070] In some embodiments, the ICI antagonizes the activity of PD-1, CTLA-4, B7, BTLA, HVEM, TIM-3, GAL-9, LAG3, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK1, CHK2, A2aR, and combinations thereof.
[0071] In some embodiments, the ICI is selected from an anti-PD-1 antibody (optionally pembrolizumab, nivolumab, cemiplimab), an anti-PD-L1 antibody (optionally atezolizumab, avelumab, durvalumab), an anti-CTLA-4 antibody (optionally ipilimumab), an anti-PD-L2 antibody, an anti-B7-H3 antibody, an anti-B7-H4 antibody, an anti-BTLA antibody, an anti-HVEM antibody, an anti-TIM-3 antibody, an anti-GAL-9 antibody, an anti-LAG3 antibody, an anti-VISTA antibody, an anti-KIR antibody, an anti-2B4 antibody, an anti-CD160 antibody, an anti-CGEN-15049 antibody, an anti-CHK1 antibody, an anti-CHK2 antibody, an anti-A2aR antibody, an anti-B-7 antibody, and a combination thereof.
[0072] In some aspects, the present invention provides a kit for treating cancer, comprising a pharmaceutical composition comprising a GM-CSF antagonist and a pharmaceutical composition comprising at least another cancer therapy selected from chemotherapy, MDSC-targeted therapy, immunotherapy, radiation therapy, and combinations thereof.
[0073] In some embodiments, the immunotherapy is an ICI selected from the following: anti-PD-1 antibody (optionally pembrolizumab, nivolumab, cemiplimab), anti-PD-L1 antibody (optionally atezolizumab, avelumab, durvalumab), anti-CTLA-4 antibody (optionally ipilimumab), anti-PD-L2 antibody, anti-B7-H3 antibody, anti-B7-H4 antibody, anti-BTLA antibody, anti-HVEM antibody, anti-TIM-3 antibody, anti-GAL-9 antibody, anti-LAG3 antibody, anti-VISTA antibody, anti-KIR antibody, anti-2B4 antibody, anti-CD160 antibody, anti-CGEN-15049 antibody, anti-CHK1 antibody, anti-CHK2 antibody, anti-A2aR antibody, anti-B-7 antibody, and combinations thereof.
[0074] definition
[0075] In order to make the present invention more easily understood, certain terms are first defined below. Additional definitions of the following terms and other terms are set forth throughout the specification. Publications and other reference materials that describe the background of the present invention and provide additional details about its practice, as mentioned herein, are incorporated herein by reference.
[0076] Antibody: As used herein, the term "antibody" refers to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, i.e., molecules that contain an antigen binding site that binds (immunoreacts with) an antigen. "Binding" or "immunoreacting with" means that the antibody reacts with the desired antigenic determinant or determinants. Antibodies include antibody fragments. Antibodies also include, but are not limited to, polyclonal, monoclonal, chimeric dAbs (domain antibodies), single chains, Fab, Fab', F(ab')2 fragments, scFv, and Fab expression libraries. Antibodies can be complete antibodies, or immunoglobulins, or antibody fragments.
[0077] Amino Acid: As used herein, the term "amino acid" refers in the broadest sense to any compound and / or substance that can be incorporated into a polypeptide chain. In some embodiments, an amino acid has the general structure H2N-C(H)(R)-COOH. In some embodiments, the amino acid is a naturally occurring amino acid. In some embodiments, the amino acid is a synthetic amino acid; in some embodiments, the amino acid is a d-amino acid; in some embodiments, the amino acid is a l-amino acid. "Standard amino acid" refers to any of the twenty standard l-amino acids commonly found in naturally occurring peptides. "Non-standard amino acid" refers to any amino acid other than a standard amino acid, whether it is synthetically prepared or obtained from a natural source. As used herein, "synthetic amino acid" encompasses chemically modified amino acids, including but not limited to salts, amino acid derivatives (e.g., amides), and / or substitutions. Amino acids, including carboxyl and / or amino terminal amino acids in peptides, can be modified by methylation, amidation, acetylation, protecting groups, and / or substitutions by other chemical groups, which modifications can alter the circulating half-life of the peptide without adversely affecting its activity. Amino acids can participate in disulfide bonds. The amino acid may contain one or more post-translational modifications, such as conjugation to one or more chemical entities (e.g., a methyl group, an acetate group, an acetyl group, a phosphate group, a formyl moiety, an isoprenoid group, a sulfate group, a polyethylene glycol moiety, a lipid moiety, a carbohydrate moiety, a biotin moiety, etc.). The term "amino acid" is used interchangeably with "amino acid residue" and may refer to a free amino acid and / or an amino acid residue of a peptide. Whether it refers to a free amino acid or a residue of a peptide is apparent from the context in which the term is used.
[0078] Improvement: As used herein, the term "improvement" refers to the prevention, reduction or alleviation of a state, or an improvement in the state of a subject. Improvement includes but does not require complete recovery or complete prevention of a disease condition. In some embodiments, improvement includes an increase in the level of a related protein or its activity that is lacking in a related disease tissue.
[0079] Approximately or approximately: As used herein, when applied to one or more target values, the term "approximately" or "approximately" refers to a value similar to the reference value. In certain embodiments, the term "approximately" or "approximately" refers to a range of values that fall within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less in either direction (greater than or less than) of the reference value, unless otherwise specified or otherwise apparent from the context (unless such number exceeds 100% of the possible values).
[0080] Delivery: As used herein, the term "delivery" encompasses both local and systemic delivery.
[0081] Improve, increase, inhibit or decrease: As used herein, the terms "improve," "increase," "inhibit," or "decrease," or grammatical equivalents, indicate a value relative to a baseline measurement, such as a measurement in the same individual prior to beginning a treatment described herein, or a measurement in a control subject (or multiple control subjects) in the absence of a treatment described herein, such as a subject administered a placebo. A "control subject" is a subject suffering from the same form of disease as the subject to be treated, who is about the same age as the subject to be treated.
[0082] "Inhibition" or "inhibiting": As used herein, "inhibition" or "inhibiting" or grammatical equivalents means a reduction, decrease or inhibition of a biological activity. Neutralization: As used herein, neutralization means a reduction or inhibition of a biological activity of the protein to which the neutralizing antibody binds, in this case GM-CSFRα, e.g., a reduction or inhibition of GM-CSF binding to GM-CSFRα, or GM-CSFRα signaling, e.g., as measured by a GM-CSFRα-mediated response. The reduction or inhibition of biological activity may be partial or complete. The extent to which an antibody neutralizes GM-CSFRα is referred to as its neutralizing potency.
[0083] Patient: The term "patient" refers to any organism to which the provided compositions can be administered, e.g., for experimental, diagnostic, preventive, cosmetic and / or therapeutic purposes. Typical patients include animals (e.g., mammals, such as mice, rats, rabbits, non-human primates and / or humans). In some embodiments, the patient is a human. Humans include both prenatal and postnatal forms.
[0084] Pharmaceutically acceptable: As used herein, the term "pharmaceutically acceptable" refers to substances which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications, commensurate with a reasonable benefit / risk ratio.
[0085] Substantial identity: The phrase "substantial identity" is used herein to refer to a comparison between amino acid or nucleic acid sequences. As will be appreciated by one of ordinary skill in the art, two sequences are generally considered to be "substantially identical" if they contain identical residues in corresponding positions. As is well known in the art, any of a variety of algorithms can be used to compare amino acid or nucleic acid sequences, including those available in commercial computer programs, such as BLASTN for nucleotide sequences, and BLASTP, gapped BLAST, and PSI-BLAST for amino acid sequences. Exemplary such programs are described in Altschul et al., Basic local alignment search tool, J Mal. Biol., 215(3):403-410, 1990; Altschul et al., Methods in Enzymology; Altschul et al., Nucleic Acids Res. 25:3389-3402, 1997; Baxevanis et al., Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins, Wiley, 1998; and Misener et al., (eds.), Bioinformatics Methods and Protocols (Methods in Molecular Biology, Vol. 132,) Humana Press, 1999. In addition to identifying identical sequences, the above programs typically provide an indication of the degree of identity. In some embodiments, two sequences are considered substantially identical if at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more of the corresponding residues of the two sequences are identical over a related stretch of residues. In some embodiments, the related stretch is the entire sequence. In some embodiments, the related stretch is at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500 or more residues.
[0086] Subject: As used herein, the term "subject" refers to a human or any non-human animal (e.g., mouse, rat, rabbit, dog, cat, cow, pig, sheep, horse, or primate). Humans include prenatal and postnatal forms. In many embodiments, the subject is a human. The subject can be a patient, which refers to a person presented to a medical provider for diagnosis or treatment of a disease. The term "subject" is used interchangeably herein with "individual" or "patient". A subject can suffer from a disease or condition or be susceptible to a disease or condition, but may or may not exhibit symptoms of the disease or condition.
[0087] Substantially: As used herein, the term "substantially" refers to the qualitative condition of exhibiting the full or nearly full extent or degree of a characteristic or property of interest. One of ordinary skill in the biological arts will appreciate that biological and chemical phenomena are rarely, if ever, completed and / or carried to completion or to achieve or avoid an absolute result. The term "substantially" is therefore used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena.
[0088] Systemic distribution or delivery: As used herein, the terms "systemic distribution," "systemic delivery," or grammatical equivalents refer to a delivery or distribution mechanism or method that affects the entire body or entire organism. Typically, systemic distribution or delivery is accomplished via the body's circulatory system, such as the blood. Compare to the definition of "local distribution or delivery."
[0089] Therapeutically effective amount: As used herein, the term "therapeutically effective amount" of a therapeutic agent means an amount that, when administered to a subject suffering from or susceptible to a disease, disorder, and / or condition, is sufficient to treat, diagnose, prevent, and / or delay the onset of the disease, disorder, and / or condition. One of ordinary skill in the art will appreciate that a therapeutically effective amount is typically administered via a dosing regimen comprising at least one unit dose.
[0090] Treatment: As used herein, the terms "treat," "treatment," or "treating" refer to any agent used to partially or completely alleviate, ameliorate, alleviate, inhibit, prevent, delay the onset of, reduce the severity of, and / or reduce the incidence of one or more symptoms or features of a particular disease, disorder, and / or condition. Treatment can be administered to subjects who do not show signs of the disease and / or show only early signs of the disease for the purpose of reducing the risk of developing pathological conditions associated with the disease. BRIEF DESCRIPTION OF THE DRAWINGS
[0091] The drawings are for illustrative purposes only and are not intended to be limiting.
[0092] Figure 1It is an exemplary bar graph illustrating a T cell proliferation assay of CD14+ cells (MDSC) from the blood of pancreatic cancer patients. Compared with those T cells cultured only in complete medium, T cell proliferation was inhibited after co-culture of healthy donor allogeneic T cells and CD14+ cells sorted from the blood of pancreatic cancer patients. After culture with anti-GM-CSFRα antibodies and CD14+ cells sorted from the blood of pancreatic cancer patients, T cell proliferation was rescued.
[0093] Figure 2 is an exemplary graph illustrating GM-CSF expression levels in different cancer cell lines.
[0094] Figure 3 For a series of exemplary bar graphs illustrating that cancer cell conditioned medium can polarize monocytes into phenotype MDSC (CD14+ cells). In order to produce tumor conditioned medium (CM), four different cell lines were inoculated and cultured according to methods known in the art. Then, in the presence of CM, CD14+ monocytes were cultured for 6 days and gene and protein expression were analyzed. Low levels of HLA-DR biomarkers indicate MDSC phenotypes. Compared with CD+14 cells (control) grown in normal culture medium, when CD14+ monocytes were incubated with conditioned medium from cancer cells expressing GM-CSF, an increase in phenotype MDSC was observed.
[0095] Figure 4 is a series of exemplary bar graphs illustrating PD-L1 expression on MDSCs cultured with various media. The data show that cancer cell conditioned medium (CM) and CM supplemented with recombinant GM-CSF can induce PD-L1 expression on MDSCs. In addition, anti-GM-CSFRα antibody (Ab) can reduce the PD-L1 expression level on MDSCs.
[0096] Figure 5A and Figure 5B is a series of exemplary bar graphs illustrating PD-L1 expression on MDSCs cultured with various media. The data show that cancer cell conditioned medium (CM) and CM supplemented with recombinant GM-CSF on day 1 can induce PD-L1 expression on MDSCs compared to MDSCs grown in normal medium (medium). In addition, anti-GM-CSFRα antibody (Ab) can reduce PD-L1 levels on MDSCs grown in CM. Figure 5A The data in show PD-L1 expression when CM and anti-GM-CSFRα antibody (Ab) were added simultaneously. PD-L1 expression was measured after 3 days of treatment. Figure 5BThe data in show PD-L1 expression when anti-GM-CSFRα antibody was added 72 hours after culture with CM. PD-L1 expression was measured after 24 hours of treatment with anti-GM-CSFRα antibody.
[0097] Figure 6 is a series of exemplary bar graphs illustrating T cell proliferation in which monocytes were treated with conditioned medium from a GM-CSF expressing cancer cell line, supplemented and not supplemented with human recombinant GM-CSF and / or anti-GM-CSFRα antibody (Ab). Monocytes were cultured for three days in conditioned medium from a GM-CSF expressing cancer cell line (CM). T cells (1×10 5 Cells). Then, stimulated T cells were co-cultured with CM-treated monocytes (at a ratio of 2:1 monocytes: T cells) in a mixed lymphocyte reaction (MLR) with or without recombinant GM-CSF (10 ng / mL) and / or anti-GM-CSFRα antibody (100 μg / mL). Stimulated T cells in IMDM medium were used as controls together with healthy monocytes. T cells were expanded for 5 days, collected and stained for CD4 and CD8, which are markers of helper T and cytotoxic T cells. Cell proliferation was measured by flow cytometry and evaluated by CFSE dilution. The left figure shows the results of T cell proliferation assays expressed as a percentage of proliferating cells, and the right figure shows the results expressed by flow cytometry as a percentage of the maximum (MFI) (signal detection of CFSE dilution in CD4+ or CD8+ cells). DETAILED DESCRIPTION
[0098] The present invention provides, inter alia, methods of treating cancer using GM-CSF antagonists by inhibiting the immunosuppressive activity of myeloid-derived suppressor cells (MDSC) in patients in need of treatment. In some embodiments, GM-CSF antagonists are used in combination with immune checkpoint inhibitors. It is contemplated that the present invention is particularly effective in treating cancers that are refractory or resistant to immune checkpoint inhibition (ICI) or advanced or metastatic cancers.
[0099] Various aspects of the present invention are described in detail in the following sections. The use of sections is not intended to limit the present invention. Each section can be applied to any aspect of the present invention. In this patent application, unless otherwise stated, the use of "or" means "and / or".
[0100] Myeloid-derived suppressor cells (MDSC)
[0101] MDSCs are a heterogeneous group of immune cells derived from the myeloid lineage. MDSCs expand strongly in pathological situations, such as chronic infection and cancer, and are distinguished from other myeloid cell types in that they have strong immunosuppressive activity rather than immunostimulatory properties. Monocytes with reduced or no HLA-DR expression, called CD14 + HLA-DR lo / neg Monocytes group into MDSCs and can alter adaptive immunity and produce immunosuppression.
[0102] MDSCs accumulate in peripheral blood, lymphoid organs, spleen, and tumor sites in cases of cancer, infection, chronic inflammation, transplantation, and autoimmunity. The specific pathways by which tumors recruit, expand, and activate MDSCs remain unknown, but there is increasing evidence for interleukins (IL-1β, IL-6, PGE2 produced by cyclooxygenase 2 (COX2), high concentrations of GM-CSF, M-CSF, vascular endothelial growth factor (VEGF), IL-10, transforming growth factor β (TGFβ), indoleamine 2,3-dioxyhenase (IDO), FLT3 ligand, and stem cell factor.
[0103] Co-culture of immune competent cells with tumor cell lines can induce tolerogenic DCs or MDSCs, as shown. Previous studies have also shown that tumor cells release GM-CSF, which induces granulocyte ROS production to suppress T cell function. In addition, in murine tumor models, the expression of programmed death ligand 1 (PD-L1) on the surface of MDSCs is increased, although the role of this in MDSC-mediated suppression remains unclear.
[0104] Programmed death ligand 1 (PD-L1)
[0105] Programmed death ligand 1 (PD-L1; also known as CD274) is an immune checkpoint protein that binds to its receptor PD-1. PD-L1 is widely expressed on various cell types, mainly on tumor cells, MDSCs, monocytes, macrophages, natural killer (NK) cells, dendritic cells (DCs), and activated T cells, as well as in immune privileged sites such as the brain, cornea, and retina. Under normal physiological conditions, activation of the PD-1 / PD-L1 signaling pathway is closely associated with the induction and maintenance of peripheral tolerance, maintenance of T cell immune homeostasis, avoidance of overactivation, and prevention of immune-mediated tissue damage. In disease states, PD-L1 interacts with its receptor programmed death 1 (PD-1) to transmit negative signals to control a series of processes of T cell-mediated cellular immune responses, including priming, growth, proliferation and apoptosis, as well as functional maturation, leading to immune escape.
[0106] Immune checkpoint inhibitors (ICIs) have changed the treatment landscape for many tumors, inducing durable responses in some cases, with significant increases in tumor mutation burden, CD8 + T cell density and PD-L1 expression have each been proposed as unique biomarkers for response to PD-1 / -L1 antagonists. One of the main challenges of immune checkpoint blocking antibodies lies in malignancies with limited T cell responses, or immune "cold" tumors. These cold tumors contain very few infiltrating T cells, are not recognized and do not trigger a strong response from the immune system, making them difficult to treat with current immunotherapies. The inventors unexpectedly discovered that GM-CSF upregulates PD-L1, contributing to immunosuppressive activity. Converting "cold" tumors to "hot" tumors is one of the milestones in cancer treatment.
[0107] GM-CSF antagonists
[0108] GM-CSF signaling
[0109] GM-CSF is a type I proinflammatory cytokine that enhances the survival and proliferation of a wide range of hematopoietic cell types. It is a growth factor that was first identified as an inducing factor for differentiation and proliferation of myeloid cells (e.g., neutrophils, basophils, eosinophils, monocytes, and macrophages) (Wicks IP and Roberts AW. Nat Rev Rheumatol. 2016, 12(1): 37-48). Studies using different methods have shown that GM-CSF overexpression is almost always accompanied by pathological changes (Hamilton JA et al. Growth Factors. 2004, 22(4): 225-31). GM-CSF enhances the transport of myeloid cells through the activated endothelium of blood vessels, and can also promote the accumulation of monocytes and macrophages in blood vessels during inflammation. GM-CSF also promotes the activation, differentiation, survival, and proliferation of monocytes and macrophages in inflammatory tissues and resident tissue macrophages. It regulates the phenotype of antigen-presenting cells in inflammatory tissues by promoting the differentiation of infiltrating monocytes into M1 macrophages and monocyte-derived dendritic cells (MoDCs). In addition, IL-23 produced by macrophages and MoDCs regulates T cell differentiation in conjunction with other cytokines such as IL-6 and IL-1.
[0110] Together with M-CSF (macrophage-colony stimulating factor), GM-CSF regulates the number and function of macrophages. Macrophages activated by GM-CSF acquire a range of effector functions, all of which identify them as inflammatory macrophages. GM-CSF-activated macrophages produce proinflammatory cytokines, including TNF, IL-1β, IL-6, IL-23 and IL-12, and chemokines such as CCL5, CCL22 and CCL24, which recruit T cells and other inflammatory cells into the tissue microenvironment.
[0111] GM-CSF receptor is a member of the haematopoietin receptor superfamily. It is a heterodimer, consisting of α and β subunits. The α subunit is highly specific to GM-CSF, while the β subunit is shared with other cytokine receptors, including IL-3 and IL-5. This is reflected in the wider tissue distribution of the β receptor subunit. The α subunit GM-CSFR is mainly expressed in bone marrow cells and non-hematopoietic cells, such as neutrophils, macrophages, eosinophils, dendritic cells, endothelial cells and respiratory epithelial cells. Full-length GM-CSFRα is a 400 amino acid type I membrane glycoprotein, which belongs to the type I cytokine receptor family, and is composed of a 22 amino acid signal peptide (position 1-22), a 298 amino acid extracellular domain (position 23-320), a transmembrane domain of position 321-345 and a 55 amino acid short intracellular domain. The signal peptide is cleaved to provide the mature form of GM-CSFRα as a 378 amino acid protein. Complementary DNA (cDNA) clones of human and mouse GM-CSFRα are available, and at the protein level, the receptor subunits have 36% identity. GM-CSF is able to bind to the α subunit alone with relatively low affinity (Kd 1-5nM), but does not bind to the β subunit alone at all. However, the presence of both α and β subunits results in a high affinity ligand receptor complex (Kd ~ 100pM). GM-CSF signaling occurs through its initial binding to the GM-CSFRα chain, followed by cross-linking with the larger subunit, the common β chain, to produce a high affinity interaction that phosphorylates the JAK-STAT pathway. This interaction can also signal through tyrosine phosphorylation and activation of the MAP kinase pathway.
[0112] Pathologically, GM-CSF has been shown to play a role in exacerbating inflammatory, respiratory and autoimmune diseases. Therefore, neutralizing the binding of GM-CSF to GM-CSFRα is a therapeutic approach to treat diseases and conditions mediated by GM-CSFR. Therefore, the present invention relates to binding members that bind to human GM-CSF or GM-CSFRα, or inhibit the binding of human GM-CSF to GM-CSFRα, and / or inhibit the signaling generated by the binding of GM-CSF ligand to the receptor. Upon ligand binding, GM-CSFR triggers stimulation of multiple downstream signaling pathways, including JAK2 / STAT5, MAPK pathways, and PI3K pathways; all are associated with the activation and differentiation of myeloid cells. The binding member can be a reversible inhibitor of GM-CSF signaling through GM-CSFR.
[0113] GM-CSF antagonists
[0114] GM-CSF antagonists suitable for the present invention include therapeutic agents that are capable of reducing, inhibiting or eliminating one or more GM-CSF-mediated signaling, including those described herein. For example, suitable GM-CSF antagonists according to the present invention include, but are not limited to, anti-GM-CSF antibodies or fragments thereof, soluble GM-CSF receptors and variants thereof, including fusion proteins, such as GM-CSF soluble receptor-Fc fusion proteins, anti-GM-CSF receptor antibodies or fragments thereof, to name a few.
[0115] In some embodiments, a suitable GM-CSF antagonist is an anti-GM-CSFRα antibody. Exemplary anti-GM-CSFRα monoclonal antibodies include those described in the following applications: International Application PCT / GB2007 / 001108 filed on March 27, 2007 and published as WO2007 / 110631, European Patent Application 120770487 filed on October 10, 2020, U.S. Application 11 / 692,008 filed on March 27, 2007, U.S. Application 12 / 294,616 filed on September 25, 2008, U.S. Application 13 / 941,40 filed on July 12, 2013. 9. U.S. application Ser. No. 14 / 753,792, filed Nov. 30, 2010, International application PCT / EP2012 / 070074, filed Oct. 10, 2012, and published as WO / 2013 / 053767, International application PCT / EP2015 / 060902, filed May 18, 2015, and published as WO2015 / 177097, International application PCT / EP2017 / 062479, filed May 23, 2017, each of which is incorporated herein by reference in its entirety. In one embodiment, the anti-GM-CSFRα monoclonal antibody is Mavrilimumab. WO2007 / 110631 reports the isolation and characterization of the anti-GM-CSFRα antibody Mavrilimumab and its variants, which share the ability to neutralize the biological activity of GM-CSFRα with high potency. The functional properties of these antibodies are thought to be attributable, at least in part, to binding to the Tyr-Leu-Asp-Phe-Gln motif at positions 226 to 230 of human GM-CSFRα, thereby inhibiting the association between GM-CSFRα and its ligand GM-CSF. Mavrilimumab is a human IgG4 monoclonal antibody designed to modulate macrophage activation, differentiation, and survival by targeting GM-CSFRα. It is a potent neutralizer of the biological activity of GM-CSFRα and has been shown to exert its therapeutic effects on leukocytes within the synovial joints of RA patients by binding to GM-CSFRα, resulting in reduced cell survival and activation. To date, the GM-CSFR antibody Mavrilimumab has shown limited efficacy in vivo in RA.
[0116] The safety profile of its use has been established in a Phase II clinical trial in rheumatoid arthritis (RA).
[0117] In certain embodiments, the antibody is composed of two light chains and two heavy chains. The heavy chain variable domain (VH) comprises the amino acid sequence identified in SEQ ID NO: 1. The light chain variable domain (VL) comprises the amino acid sequence identified in SEQ ID NO: 2. The heavy chain and light chain each comprise a complementary determining region (CDR) and a framework region in the following arrangement:
[0118] FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4
[0119] The Maverick antibody heavy chain comprises CDRs: HCDR1, HCDR2, HCDR3, as identified by the amino acid sequences in SEQ ID NOs: 3, 4, and 5, respectively. The light chain comprises CDRs: LCDR1, LCDR2, LCDR3, as identified by the amino acid sequences in SEQ ID NOs: 6, 7, and 8, respectively.
[0120] Anti-GM-CSFRα heavy chain variable domain amino acid sequence
[0121] QVQLVQSGAEVKKPGASVKVSCKVSGYTLTELSIHWVRQAPGKGLEWMGGFDPEENEIVYAQRFQGRVTMTEDTSTDTAYMELSSLRSEDTAVYYCAIVGSFSPLTLGLWGQGTMVTVSS(SEQ ID NO:1)
[0122] Anti-GM-CSFRα light chain variable domain amino acid sequence
[0123] QSVLTQPPSVSGAPGQRVTISCTGSGSNIGAPYDVSWYQQLPGTAPKLLIYHNNKRPSGVPDRFSGSKTSASLAITGLQAEDEADYYCATVEAGLSGSVFGGGTKLTVL(SEQ ID NO:2)
[0124] Anti-GM-CSFRa heavy chain variable domain CDR1 (HCDR1) amino acid sequence
[0125] ELSIH (SEQ ID NO: 3)
[0126] Anti-GM-CSFRα Heavy Chain Variable Domain CDR2 (HCDR2) Amino Acid Sequence
[0127] GFDPEENEIVYAQRFQG(SEQ ID NO:4)
[0128] Anti-GM-CSFRα heavy chain variable domain CDR3 (HCDR3) amino acid sequence
[0129] VGSFSPLTLGL (SEQ ID NO:5)
[0130] Anti-GM-CSFRα light chain variable domain CDR 1 (LCDR1) amino acid sequence
[0131] TGSGSNIGAPYDVS (SEQ ID NO: 6)
[0132] Anti-GM-CSFRα light chain variable domain CDR 2 (LCDR2) amino acid sequence
[0133] HNNKRPS (SEQ ID NO:7)
[0134] Anti-GM-CSFRa light chain variable domain CDR3 (LCDR3) amino acid sequence
[0135] ATVEAGLSGSV (SEQ ID NO: 8)
[0136] In some embodiments, the anti-GM-CSFRα antibody for cancer treatment is a variant of Maverickumab selected from the GM-CSFα binding members disclosed in applications WO2007 / 11063 and WO2013053767, which are incorporated by reference in their entirety.
[0137] In some embodiments, the anti-GM-CSFRα antibody for cancer treatment comprises a CDR amino acid sequence that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to one or more of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8.
[0138] In some embodiments, the anti-GM-CSFRα antibody comprises a light chain variable domain having an amino acid sequence at least 90% identical to SEQ ID NO: 2 and a heavy chain variable domain having an amino acid sequence at least 90% identical to SEQ ID NO: 1. In some embodiments of the invention, the anti-GM-CSFRα antibody has a light chain variable domain amino acid sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to SEQ ID NO: 2, and a heavy chain variable domain amino acid sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to SEQ ID NO: 1. In some embodiments of the present invention, the anti-GM-CSFRα antibody comprises a light chain variable domain having the amino acid sequence shown in SEQ ID NO: 2, and a heavy chain variable domain having the amino acid sequence shown in SEQ ID NO: 1. In some embodiments of the present invention, the heavy chain constant region of the anti-GM-CSFRα antibody comprises a CH1, hinge and CH2 domains derived from an IgG4 antibody, which are fused to a CH3 domain derived from an IgG1 antibody. In some embodiments of the present invention, the heavy chain constant region of the anti-GM-CSFRα antibody is or is derived from an IgG1, IgG2 or IgG4 heavy chain constant region. In some embodiments of the present invention, the light chain constant region of the anti-GM-CSFRα antibody is or is derived from a λ or κ light chain constant region.
[0139] In some embodiments, the anti-GM-CSFRα inhibitor is a fragment of the maverickumab antibody. In some embodiments, the inhibitor comprises a single chain variable fragment (ScFv) comprising at least any one of the CDR sequences of SEQ ID NO: 3, 4, 5, 6, 7, or 8. In some embodiments, the inhibitor is a fusion molecule comprising at least any one of the CDR sequences of SEQ ID NO: 3, 4, 5, 6, 7, or 8. In some embodiments, the anti-GM-CSFRα inhibitor sequence is a bispecific antibody comprising at least one of the CDR sequences of SEQ ID NO: 3, 4, 5, 6, 7, or 8.
[0140] In other embodiments, suitable GM-CSF antagonists are anti-GM-CSF antibodies. Exemplary anti-GM-CSF monoclonal antibodies include those described in the following applications: International Application PCT / EP2006 / 004696, filed on May 17, 2006, and published as WO2006 / 122797, International Application PCT / EP2016 / 076225, filed on October 31, 2016, and published as WO2017 / 076804, and International Application PCT / US2018 / 053933, filed on October 2, 2018, and published as WO / 2019 / 070680, which are incorporated herein by reference in their entirety. In one embodiment, the anti-GM-CSF monoclonal antibody is otilimab.
[0141] The anti-GM-CSFRα or anti-GM-CSF antibodies of the present disclosure may be multispecific, such as bispecific. The antibody may be mammalian (e.g., human or mouse), humanized, chimeric, recombinant, synthetically produced, or naturally isolated. Exemplary antibodies of the present disclosure include, but are not limited to, IgG (e.g., IgG1, IgG2, IgG3, and IgG4), IgM, IgA (e.g., IgA1, IgA2, and IgAsec), IgD, IgE, Fab, Fab′, Fab′2, F(ab′)2, Fd, Fv, Feb, scFv, scFv-Fc, and SMIP binding portions. In certain embodiments, the antibody is a scFv. The scFv may include, for example, a flexible linker that allows the scFv to be oriented in different directions to achieve antigen binding. In various embodiments, the antibody can be a cytosolic stable scFv or intrabody that retains its structure and function in the reducing environment inside the cell (see, e.g., Fisher and DeLisa, J. Mol. Biol. 385(1):299-311, 2009; incorporated herein by reference). In specific embodiments, the scFv is converted to an IgG or chimeric antigen receptor according to methods known in the art. In embodiments, the antibody binds both a denatured protein target and a native protein target. In embodiments, the antibody binds to a denatured or native protein.
[0142] In most mammals, including humans, a complete antibody has at least two heavy chains (H) and two light chains (L) connected by disulfide bonds. Each heavy chain consists of a heavy chain variable region (VH) and a heavy chain constant region (CH). The heavy chain constant region consists of three domains (CH1, CH2 and CH3) and a hinge region between CH1 and CH2. Each light chain consists of a light chain variable region (VL) and a light chain constant region (CL). The light chain constant region consists of one domain, CL. The VH and VL regions can be further subdivided into hypervariable regions, called complementarity determining regions (CDRs), which are interspersed with more conserved regions, called framework regions (FRs). Each VH and VL consists of three CDRs and four FRs arranged from the amino terminus to the carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain binding domains that interact with antigens.
[0143] Antibodies include all known forms of antibodies and other protein scaffolds with antibody-like properties. For example, anti-GM-CSFRα antibodies can be monoclonal antibodies, polyclonal antibodies, human antibodies, humanized antibodies, bispecific antibodies, monovalent antibodies, chimeric antibodies, or protein scaffolds with antibody-like properties, such as fibronectin or ankyrin repeats. The antibody can have any of the following isotypes: IgG (e.g., IgG1, IgG2, IgG3, and IgG4), IgM, IgA (e.g., IgA1, IgA2, and IgAsec), IgD, or IgE.
[0144] Antibody fragments may include one or more segments derived from antibodies. Segments derived from antibodies may retain the ability to specifically bind to specific antigens. Antibody fragments may be, for example, Fab, Fab', Fab'2, F(ab')2, Fd, Fv, Feb, scFv or SMIP. Antibody fragments may be, for example, bifunctional antibodies, trifunctional antibodies, affibodies, nanobodies, aptamers, domain antibodies, linear antibodies, single-chain antibodies, or any of a variety of multispecific antibodies formed by antibody fragments.
[0145] Examples of antibody fragments include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; (ii) a F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment, a fragment consisting of the VH and CH1 domains; (iv) a Fv fragment, a fragment consisting of the VL and VH domains of a single arm of an antibody; (v) a dAb fragment: a fragment comprising the VH and VL domains; (vi) a dAb fragment: a fragment of the VH domain; (vii) a dAb fragment: a fragment of the VL domain; (viii) isolated complementarity determining regions (CDRs); and (ix) a combination of two or more isolated CDRs, which may optionally be joined by one or more synthetic linkers. In addition, although the two domains VL and VH of the Fv fragment are encoded by separate genes, the two domains can be joined using recombinant methods, for example, by a synthetic linker that enables the two domains to be expressed as a single protein chain, in which the VL region and the VH region are paired to form a monovalent binding portion (called a single-chain Fv (scFv)). Antibody fragments can be obtained using conventional techniques known to those skilled in the art, and in some cases, can be used in the same manner as intact antibodies. Antigen-binding fragments can be produced by recombinant DNA technology or by enzymatic or chemical cleavage of intact immunoglobulins. Antibody fragments may also include any of the antibody fragments described above, wherein the C-terminal amino acid, the N-terminal amino acid, or the amino acids separating the individual fragments are additionally added.
[0146] If an antibody includes one or more antigenic determining regions or constant regions derived from a first species and one or more antigenic determining regions or constant regions derived from a second species, it may be referred to as chimeric. Chimeric antibodies may be constructed, for example, by genetic engineering. Chimeric antibodies may include immunoglobulin gene segments belonging to different species (e.g., from a mouse and a human).
[0147] The antibody can be a human antibody. A human antibody refers to a binding portion having a variable region, wherein both the framework region and the CDR region are derived from human immunoglobulin sequences. In addition, if the antibody contains a constant region, the constant region is also derived from a human immunoglobulin sequence. A human antibody can include amino acid residues not identified in a human immunoglobulin sequence, such as one or more sequence variants, such as mutations. Variants or additional amino acids can be introduced, for example, by human manipulation. The human antibodies of the present disclosure are not chimeric.
[0148] Antibodies can be humanized, meaning that antibodies comprising one or more antigenic determining regions (e.g., at least one CDR) substantially derived from non-human immunoglobulins or antibodies are manipulated to include at least one immunoglobulin domain substantially derived from human immunoglobulins or antibodies. Antibodies can be humanized using conversion methods as described herein, such as by inserting an antigen recognition sequence from a non-human antibody encoded by a first vector into a human framework encoded by a second vector. For example, a first vector can include a polynucleotide and a site-specific recombination motif encoding a non-human antibody (or its fragment), and a second vector can include a polynucleotide encoding a human framework and a site-specific recombination complementary to the site-specific recombination motif on the first vector. The site-specific recombination motif can be positioned on each vector so that a recombination event results in one or more antigenic determining regions from a non-human antibody being inserted into a human framework, thereby forming a polynucleotide encoding a humanized antibody.
[0149] In certain embodiments, the antibody is converted from scFv to IgG (e.g., IgG1, IgG2, IgG3, and IgG4). Various methods exist in the art for converting scFv fragments to IgG. One such method for converting scFv fragments to IgG is disclosed in U.S. Patent Application Publication No. 20160362476, the contents of which are incorporated herein by reference.
[0150] Combination therapy
[0151] Immune checkpoint inhibitors (ICIs)
[0152] In some embodiments, methods of treating cancer according to the present invention comprise administering to a subject in need thereof a GM-CSF antagonist in combination with an ICI.
[0153] In some embodiments, the ICI is a biotherapeutic agent or a small molecule. In some embodiments, the ICI is a monoclonal antibody, a humanized antibody, a fully human antibody, a fusion protein, or a combination thereof.
[0154] In some embodiments, ICI inhibits a checkpoint protein, which may be CTLA-4, PD-L1, PD-L2, PD-1, B7-H3, B7-H4, BTLA, HVEM, TIM-3, GAL-9, LAG3, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK1, CHK2, A2aR, B-7 family ligands, or a combination thereof. In some embodiments, ICI interacts with a ligand of a checkpoint protein, which may be CTLA-4, PD-L1, PD-L2, PD-1, B7-H3, B7-H4, BTLA, HVEM, TIM-3, GAL-9, LAG3, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK 1, CHK2, A2aR, B-7 family ligands, or a combination thereof.
[0155] In some embodiments, ICI is an anti-CTLA-4 antibody. In some embodiments, ICI is an anti-PD-L1 antibody. In some embodiments, ICI is an anti-PD-L2 antibody. In some embodiments, ICI is an anti-PD-1 antibody. In some embodiments, ICI is an anti-B7-H3 antibody. In some embodiments, ICI is an anti-B7-H4 antibody. In some embodiments, ICI is an anti-BTLA antibody. In some embodiments, ICI is an anti-HVEM antibody. In some embodiments, ICI is an anti-TIM-3 antibody. In some embodiments, ICI is an anti-GAL-9 antibody. In some embodiments, ICI is an anti-LAG-3 antibody. In some embodiments, ICI is an anti-VISTA antibody. In some embodiments, ICI is an anti-KIR antibody. In some embodiments, ICI is an anti-2B4 antibody. In some embodiments, ICI is an anti-CD160 antibody. In some embodiments, ICI is an anti-CGEN-15049 antibody. In some embodiments, ICI is an anti-CHK1 antibody. In some embodiments, ICI is an anti-CHK2 antibody. In some embodiments, ICI is an anti-A2aR antibody. In some embodiments, the checkpoint inhibitor is an anti-B-7 antibody.
[0156] In some embodiments, the PD-1 antibody is pembrolizumab. In some embodiments, the PD-1 antibody is nivolumab. In some embodiments, the PD-1 antibody is cemiplizumab. In some embodiments, the PD-L1 antibody is atezolizumab. In some embodiments, the PD-L1 antibody is avelumab. In some embodiments, the PD-L1 antibody is durvalumab. In some embodiments, the CTLA-4 antibody is ipilimumab.
[0157] Additional therapeutic agents
[0158] In some embodiments, the method of treating cancer according to the present invention comprises administering to a subject in need thereof a GM-CSF antagonist in combination with an additional therapeutic agent. In certain embodiments, the additional agent is a cancer therapy comprising chemotherapy and / or radiation therapy. In certain embodiments, the additional therapeutic agent comprises a recombinant protein or a monoclonal antibody. In certain embodiments, the recombinant protein or monoclonal antibody comprises Etaracizumab (Abegrin), Tacatuzumab tetraxetan, Bevacizumab (Avastin), Labetuzumab, Cetuximab (Erbitux), Obinutuzumab (Gazyva), Trastuzumab (Herceptin), Clivatuzumab, Trastuzumab emtansine (Kadcyla), Ramucirumab, Rituximab (MabThera, Rituxan), Gemtuzumab ozogamicin (Gemtuzumab), ozogamicin) (Mylotarg), Pertuzumab (Omnitarg), Girentuximab (Rencarex), or Nimotuzumab (Theracim, Theraloc).
[0159] In certain embodiments, the GM-CSF antagonist comprises an immunomodulator targeting a checkpoint inhibitor, as described above in the section on checkpoint inhibitors. In certain embodiments, the immunomodulator comprises nivolumab, ipilimumab, atezolizumab, or pembrolizumab. In certain embodiments, the additional therapeutic agent is a chemotherapeutic agent. In certain embodiments, the chemotherapeutic agent is an alkylating agent (e.g., cyclophosphamide, ifosfamide, chlorambucil, busulfan, melphalan, mechlorethamine, uramustine, thiotepa, nitrosoureas, or temozolomide), an anthracycline (e.g., doxorubicin, adriamycin, daunorubicin, epirubicin, or mitoxantrone), a cytoskeletal disruptor (e.g., paclitaxel or docetaxel), a histone deacetylase inhibitor (e.g., vorinostat or romidepsin), an inhibitor of topoisomerase (e.g., irinoteca, topoisomerase inhibitors, or sirolimus ... cytoskeletal disruptor (e.g., paclitaxel or docetaxel), a cytoskeletal disruptor (e.g., paclitaxel or docetaxel), a cytoskeletal disruptor (e.g., paclitaxel or docetaxel), a cytoskeletal disruptor (e.g., paclitaxel or docetaxel), a cytoskeletal disruptor (e.g., paclitaxel or docetaxel), a cytoskeletal disruptor (e.g., paclitaxel or docetaxel), a cytoskeletal disruptor (e.g., paclitax oxadiazine, ... In some embodiments, the chemotherapeutic agent is a nucleoside analog. In some embodiments, the chemotherapeutic agent is gemcitabine. In certain embodiments, the additional therapeutic agent is radiation therapy.
[0160] Cancer Treatment
[0161] The present invention can be used to treat various cancers, particularly those that are refractory or resistant to immune checkpoint inhibition (ICI), or advanced or metastatic cancers.
[0162] In some embodiments, the cancer is any solid tumor or liquid cancer, including genitourinary cancer (e.g., prostate cancer, renal cell carcinoma, bladder cancer), gynecological cancer (e.g., ovarian cancer, cervical cancer, endometrial cancer), lung cancer, gastrointestinal cancer (e.g., non-metastatic or metastatic colorectal cancer, pancreatic cancer, gastric cancer, esophageal cancer, hepatocellular carcinoma, cholangiocarcinoma), head and neck cancer (e.g., head and neck squamous cell carcinoma), brain cancer, including malignant glioma and brain metastasis, malignant mesothelioma, non-metastatic or metastatic breast cancer (e.g., hormone-refractory metastatic breast cancer), malignant melanoma, Merkel cell carcinoma or bone and soft tissue sarcoma, and hematological tumors, such as multiple myeloma, acute myeloid leukemia, chronic myelogenous leukemia, myelodysplastic syndrome, and acute lymphocytic leukemia. In some embodiments, the disease is non-small cell lung cancer (NSCLC), breast cancer (e.g., stage IV breast cancer, hormone-refractory metastatic breast cancer), head and neck cancer (e.g., head and neck squamous cell carcinoma), metastatic colorectal cancer, hormone-sensitive or hormone-refractory prostate cancer, colorectal cancer (e.g., stage IV colorectal cancer), ovarian cancer, hepatocellular carcinoma, renal cell carcinoma, soft tissue sarcoma, or small cell lung cancer.
[0163] As used herein, the term "cancer" refers to a broad class of disorders characterized by hyperproliferative cell growth in vitro (e.g., transformed cells) or in vivo. Conditions that can be treated or prevented by the compositions and methods of the present invention include, for example, a variety of tumors, including benign or malignant tumors, a variety of hyperplasias, and the like. The compounds and methods of the present invention can inhibit and / or reverse the undesirable hyperproliferative cell growth involved in such conditions.
[0164] Examples of cancer include acute lymphocytic leukemia, adult; acute lymphocytic leukemia, childhood; acute myeloid leukemia, adult; adrenocortical carcinoma; adrenocortical carcinoma, childhood; AIDS-related lymphoma; AIDS-related malignancies; anal cancer; astrocytoma, cerebellum, childhood; astrocytoma, cerebral, childhood; biliary tract cancer, extrahepatic; bladder cancer; bladder cancer, childhood; bone cancer, osteosarcoma / malignant fibrous histiocytoma; brain stem glioma, childhood; brain tumor, adult; brain tumor, brain stem glioma, childhood; brain tumor, cerebellar astrocytoma, childhood; brain tumor, cerebral astrocytoma / malignant glioma, childhood; brain tumor, ependymoma, childhood; brain tumor, medulloblastoma, childhood; brain tumor, supratentorial primitive neuroectodermal tumor, childhood; brain tumor, Visual Pathway and Hypothalamic Glioma, Childhood; Brain Tumor, Childhood (Other); Breast Cancer; Breast Cancer and Pregnancy; Breast Cancer, Childhood; Breast Cancer, Male; Bronchial Adenoma / Carcinoid, Childhood: Carcinoma, Childhood; Carcinoma, Gastrointestinal; Carcinoma, Adrenal Cortex; Carcinoma, Islet Cell; Carcinoma of Unknown Primary; Central Nervous System Lymphoma, Primary; Cerebellar Astrocytoma, Childhood; Cerebral Astrocytoma / Glioma, Childhood; Cervical Cancer; Childhood Cancer; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Chronic Myeloproliferative Disorders; Tenosynovial Clear Cell Sarcoma; Colon Cancer; Colorectal Cancer, Childhood; Cutaneous T-Cell Lymphoma; Endometrial Cancer; Ependymoma, Childhood; Epithelial Cancer, Ovarian; Esophageal Cancer; Esophageal Cancer, Childhood; Ewing's Family of Tumors of Tumors); Extracranial Germ Cell Tumor, Childhood; Extragonadal Germ Cell Tumor; Extrahepatic Biliary Tract Cancer; Eye Cancer, Intraocular Melanoma; Eye Cancer, Retinoblastoma; Gallbladder Cancer; Gastric (Stomach) Cancer; Gastric (Stomach) Cancer, Childhood; Gastrointestinal Carcinoid Tumors; Germ Cell Tumor, Extracranial, Childhood; Germ Cell Tumor, Extragonadal; Germ Cell Tumor, Ovarian; Gestational Trophoblastic Tumor; Glioma, Brainstem, Childhood; Glioma, Visual Pathway and Hypothalamus, Childhood; Hairy Cell Leukemia; Head and Neck Cancer; Hepatocellular (Liver) Cancer, Adult (Primary); Hepatocellular (Liver) Cancer, Childhood (Primary); Hodgkin's Lymphoma Lymphoma, adult; Hodgkin's lymphoma, childhood; Hodgkin's lymphoma during pregnancy; Hypothalamic and visual pathway glioma, childhood; Intraocular melanoma; Islet cell carcinoma (endocrine pancreas); Kaposi's sarcoma; Kidney cancer; Laryngeal cancer; Laryngeal cancer, childhood; Leukemia, acute lymphoblastic, adult; Leukemia, acute lymphoblastic, childhood; Leukemia, acute myeloid, adult; Leukemia, acute myeloid, childhood; Leukemia, chronic lymphocytic; Leukemia, chronic myeloid; Leukemia, hairy cell; Lip and oral cavity cancer; Liver cancer, adult (primary);Liver cancer, childhood (primary); Lung cancer, non-small cell; Lung cancer, small cell; Lymphocytic leukemia, acute, adult; Lymphocytic leukemia, acute, childhood; Lymphocytic leukemia, chronic; Lymphoma, AIDS-related; Lymphoma, central nervous system (primary); Lymphoma, cutaneous T-cell; Lymphoma, Hodgkin's, adult; Lymphoma, Hodgkin's, childhood; Lymphoma, Hodgkin's during pregnancy; Lymphoma, non-Hodgkin's, adult; Lymphoma, non-Hodgkin's, childhood; Lymphoma, non-Hodgkin's during pregnancy; Lymphoma, primary central nervous system; Macroglobulinemia, Waldenstrom's; Breast cancer, male; Malignant mesothelioma, adult; Malignant mesothelioma, childhood; malignant thymoma; medulloblastoma, childhood; melanoma; melanoma, intraocular; Merkel cell carcinoma; mesothelioma, malignant; metastatic squamous neck carcinoma with occult primary; multiple endocrine neoplasms syndrome, childhood; multiple myeloma / plasma cell neoplasms; mycosis fungoides; myelodysplastic syndrome; myelogenous leukemia, chronic; myeloid leukemia, acute, childhood; myeloma, multiple; myeloproliferative disorders, chronic; nasal cavity and paranasal sinus cancer; nasopharyngeal carcinoma; nasopharyngeal carcinoma, childhood; neuroblastoma; neurofibroma; non-Hodgkin's lymphoma, adult; non-Hodgkin's lymphoma, childhood; non-Hodgkin's lymphoma during pregnancy; non-small cell lung cancer; oral cancer, childhood; oral cavity and lip cancer; oral Pharyngeal cancer; osteosarcoma / malignant fibrous histiocytoma of bone; ovarian cancer, childhood; ovarian epithelial cancer; ovarian germ cell tumor; ovarian tumor of low malignant potential; pancreatic cancer; pancreatic cancer, childhood; pancreatic cancer, islet cell; paranasal sinus and nasal cavity cancer; parathyroid cancer; penile cancer; pheochromocytoma; pineal and supratentorial primitive neuroectodermal tumor, childhood; pituitary tumor; plasma cell neoplasm / multiple myeloma; pleuropulmonary blastoma; pregnancy and breast cancer; pregnancy and Hodgkin's lymphoma; pregnancy and non-Hodgkin's lymphoma; primary central nervous system lymphoma; primary liver cancer, adult; primary liver cancer, childhood; prostate cancer; rectal cancer; renal cell (kidney) cancer; renal cell carcinoma, childhood; renal pelvis and ureter, transitional cell carcinoma; retinoblastoma; transverse striamuscarinoma, childhood; salivary gland cancer; salivary gland cancer, childhood; sarcoma, Ewing's family of tumors; sarcoma, Kaposi's; sarcoma (osteosarcoma) / malignant fibrous histiocytoma of bone; sarcoma, rhabdomyosarcoma, childhood; sarcoma, soft tissue, adult; sarcoma, soft tissue, childhood; Sezary syndrome; skin cancer; skin cancer, childhood; skin cancer (melanoma); skin cancer, Merkel cell; small cell lung cancer; small intestine cancer; soft tissue sarcoma, adult; soft tissue sarcoma, childhood; squamous neck cancer with occult primary metastasis; stomach (gastric) cancer; stomach (gastric) cancer, childhood; supratentorial primitive neuroectodermal tumor, childhood; T-cell lymphoma, skin; testicular cancer; thymoma, childhood; thymoma, malignant; thyroid cancer;Thyroid cancer, childhood; Transitional cell carcinoma of the renal pelvis and ureter; Trophoblastic tumor, pregnancy; Unknown primary site, cancer, childhood; Unusual childhood cancers; Ureter and renal pelvis, transitional cell carcinoma; Urethra cancer; Uterine sarcoma; Vaginal cancer; Visual pathway and hypothalamic glioma, childhood; Vulvar cancer; Waldenstrom's macroglobulinemia; and Wilms' tumor.
[0165] Pharmaceutical compositions and administration
[0166] The antibodies or agents of the present invention (also referred to herein as "active compounds") and their derivatives, fragments, analogs and homologues may be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise an antibody or agent and a pharmaceutically acceptable carrier. As used herein, the term "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents and absorption delaying agents, etc. that are compatible with pharmaceutical administration. Suitable carriers are described in the latest edition of Remington's Pharmaceutical Sciences, a standard reference textbook in the field, which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, Ringer's solution, dextrose solution and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. In addition to the case where any conventional media or agents are incompatible with the active compound, the use of media or agents in the composition is envisioned. Supplementary active compounds can also be incorporated into the compositions.
[0167] The pharmaceutical composition of the present invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, such as intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (i.e., topical), transmucosal, and rectal administration. Solutions or suspensions for parenteral, intradermal, or subcutaneous administration may include the following components: a sterile diluent, such as water for injection, saline solution, fixed oil, polyethylene glycol, glycerol, propylene glycol, or other synthetic solvents; antibacterial agents, such as benzyl alcohol or methyl paraben; antioxidants, such as ascorbic acid or sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid (EDTA); buffers, such as acetates, citrates, or phosphates; and agents for adjusting tonicity, such as sodium chloride or dextrose. pH can be adjusted with an acid or a base, such as hydrochloric acid or sodium hydroxide. Parenteral preparations can be sealed in ampoules, disposable syringes, or multiple-dose vials made of glass or plastic.
[0168] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL ㈤ (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, a polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, etc.), and suitable mixtures thereof. Appropriate fluidity can be maintained, for example, by the use of a coating such as lecithin, by maintaining a desired particle size in the case of a dispersion, and by the use of a surfactant. Protection against the action of microorganisms can be achieved by various antibacterial and antifungal agents (e.g., parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, etc.). In many cases, it is preferred to include an isotonic agent, such as a sugar, a polyol (e.g., mannitol, sorbitol), or sodium chloride in the composition. Prolonged absorption of the injectable composition can be achieved by including in the composition an agent that delays absorption, such as aluminum monostearate and gelatin.
[0169] Sterile injectable solutions can be prepared by incorporating the required amount of active compound into a suitable solvent as needed with one or a combination of the above-listed ingredients, followed by filtration sterilization. Typically, dispersions are prepared by incorporating the active compound into a sterile vehicle containing a basic dispersion medium and other ingredients required from those listed above. In the case of sterile powders for the preparation of sterile injectable solutions, the preparation method is vacuum drying and freeze drying, which produces a powder of the active ingredient plus any additional desired ingredients from its previous sterile filtered solution.
[0170] Oral compositions typically include an inert diluent or edible carrier. They can be sealed in gelatin capsules or compressed into tablets. For oral therapeutic administration, the active compound can be incorporated with an excipient and used in tablet, dragee or capsule form. Oral compositions can also be prepared using a fluid carrier suitable for use as a mouthwash, wherein the compound in the fluid carrier is orally administered and gargled and spit out or swallowed. Pharmaceutically compatible binding agents and / or adjuvant materials can be included as part of the composition. Tablets, pills, capsules, dragees, and the like may contain any of the following ingredients, or compounds of a similar nature: binders such as microcrystalline cellulose, gum tragacanth, or gelatin; excipients such as starch or lactose; disintegrants such as alginic acid, sodium starch glycolate (Primogel), or corn starch; lubricants such as magnesium stearate or Sterotes; glidants such as colloidal silicon dioxide; sweeteners such as sucrose or saccharin; or flavorings such as peppermint, methyl salicylate, or orange flavoring.
[0171] For administration by inhalation, the compounds are delivered in the form of an aerosol spray from a pressured container or dispenser that contains a suitable propellant, eg, a gas such as carbon dioxide, or a nebulizer.
[0172] Systemic administration can also be carried out by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants suitable for the barrier to be penetrated can be used in the formulation. The penetrants are generally known in the art, and for example, for transmucosal administration, include detergents, bile salts and fusidic acid derivatives. Transmucosal administration can be achieved by using nasal sprays or suppositories. As is generally known in the art, for transdermal administration, the active compound is formulated into an ointment, salves, gel or cream.
[0173] The active compounds may also be prepared in the form of suppositories (eg, with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
[0174] In one embodiment, the active compound is prepared together with a carrier that will protect the compound from rapid elimination from the body, such as a controlled release formulation, including an implant and a microencapsulated delivery system. Biodegradable biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters and polylactic acid can be used. The method for preparing such formulations is obvious to those skilled in the art. The material can also be commercially available from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (liposomes comprising monoclonal antibodies against viral antigens targeting infected cells) can also be used as pharmaceutically acceptable carriers. These formulations can be prepared according to methods known to those skilled in the art, such as those described in U.S. Patent No. 4,522,811.
[0175] It is particularly advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. As used herein, dosage unit form refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the present invention are dictated by and directly dependent on the unique characteristics of the active compound and the specific therapeutic effect to be achieved, and the inherent limitations of the art in compounding such active compounds for treating individuals.
[0176] The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.
[0177] Examples
[0178] The present invention is further illustrated by the slides accompanying this specification, but is not limited thereto. Although certain compounds, compositions and methods of the present invention have been specifically described according to certain embodiments, the following examples are only used to illustrate the present invention and are not intended to limit it.
[0179] Example 1. Anti-GM-CSFRα antibody rescues T cell proliferation
[0180] The studies in this example demonstrate that GM-CSF antagonists can rescue the suppressive potential of myeloid cell populations on T cell proliferation.
[0181] CDCD14+ cells were measured for T cell proliferation with or without anti-GM-CSFRα antibody treatment. In brief, CD14+ (MDSC) cells were isolated from blood samples (PBMC) obtained from pancreatic cancer patients according to methods known in the art. The isolated CD14+ cells were treated with anti-GM-CSFRα antibody for 48 hours. Next, CD3+ T cells labeled with carboxy-fluorescein diacetate disuccinimidyl ester (CSE) were co-cultured with anti-GM-CSFRα antibody-treated or untreated CD14+ cells for 96 hours, and proliferation was determined by CFSE dilution (splitting cells). T cells without co-culture were used as negative controls.
[0182] like Figure 1 As shown in , T cell proliferation was significantly inhibited after culture with untreated CD14+ cells. On the other hand, CD14+ cells treated with anti-GM-CSFRα antibody showed increased T cell proliferation, suggesting that the addition of anti-GM-CSFRα antibody rescued T cell proliferation and prevented the suppressive potential of MDSC.
[0183] Example 2. Cancer cell conditioned medium polarizes monocytes into phenotype MDSC
[0184] In this study, various cancer cell lines were used to elucidate the phenotype of MDSC (HLA-DR 低 ) increase.
[0185] Analysis of GM-CSF expression in cancer cell lines. In this particular study, GM-CSF expression was measured in two colorectal cancer (HCT116 and SW-480), two pancreatic cancer (Panc-1 and Capan-1), cervical adenocarcinoma (HeLa), and malignant melanoma (A375) cell lines. Figure 2 As shown in , cancer cell lines express GM-CSF at different levels. In particular, SW480 and Capan-1 have relatively high GM-CSF expression, while HeLa cells have relatively low GM-CSF expression.
[0186] In order to produce tumor-conditioned medium (CM), cell lines were inoculated and cultured according to methods known in the art. Then, CD14+ cells were cultured for 6 days in the presence of CM and gene and protein expression were analyzed. Low levels of HLA-DR biomarkers indicated MDSC phenotypes. Figure 3 The results show that there is an increase in phenotypic MDSCs when CD14+ monocytes are incubated with conditioned medium from cancer cells expressing GM-CSF compared to CD14+ cells grown in normal medium. The results show that CM from cancer cell lines with high GM-CSF expression has a high induction of MDSCs, indicating that GM-CSF helps monocytes polarize into phenotypic MDSCs.
[0187] Example 3. Anti-GM-CSFRα antibody blocks PD-L1 upregulation in MDSCs
[0188] The studies in this example demonstrate the inventors' unexpected discovery that GM-CSF induces the expression of PD-L1 on phenotypic MDSCs. Notably, treatment with a GM-CSF antagonist was sufficient to inhibit the expression of PD-L1 on monocytes treated with conditioned medium (CM) from cancer cell lines expressing GM-CSF.
[0189] One of the main challenges of immune checkpoint blocking antibodies lies in malignancies with limited T cell responses, or immune "cold" tumors. These cold tumors contain very few infiltrating T cells, are not recognized, and do not trigger a strong response from the immune system, making them difficult to treat with current immunotherapy. The inventors unexpectedly discovered that GM-CSF upregulates PD-L1, a checkpoint protein on the surface of MDSCs that contributes to immunosuppressive activity. The studies in this example show that anti-GM-CSFRα antibodies can be used to convert "cold" tumors into "hot" tumors, potentially increasing the effectiveness and sensitivity of immunotherapy.
[0190] In this study, various cancer cell lines were used to evaluate changes in PD-L1 expression levels on MDSCs when CD14+ monocytes were incubated with conditioned media from cancer cells expressing GM-CSF. Figure 4 As shown in , the addition of conditioned medium from cancer cell lines expressing GM-CSF to CD14+ monocytes increased PD-L1 expression levels compared to baseline (medium only). The HeLa cell line, which exhibits low GM-CSF expression levels (see Figure 2) does not regulate PD-L1 expression. Adding a combination of recombinant GM-CSF and CM (CM+GM-CSF) increased the expression of PD-L1, indicating that GM-CSF induces the expression of PD-L1 on phenotypic MDSCs. The spikes in PDPD-L1 are more obvious in cell lines (e.g., Panc-1 and HeLa cells) with low baseline PD-L1 expression and only CM. The effect of anti-GM-CSFRα antibodies on PD-L1 expression was also examined. Treatment of MDSCs with anti-GM-CSFRα antibodies in CM in the absence or presence of recombinant GM-CSF (CM+Ab and CM+GM-CSF+Ab, respectively) resulted in a significant decrease in PD-L1 levels compared to only CM or CM+GM-CSF. These data show that anti-GM-CSFRα antibodies inhibit PD-L1 upregulation in CDCD14+ monocytes (MDSCs) treated with conditioned medium from cancer cell lines expressing GM-CSF.
[0191] Example 4. Anti-GM-CSFRα antibody inhibits PD-L1 expression in MDSCs
[0192] The studies in this Example show that GM-CSF antagonists are able to inhibit PD-L1 expression on MDSCs treated with culture medium (CM) from cancer cell lines expressing GM-CSF, whether the GM-CSF antagonist is added simultaneously with CM treatment or the GM-CSF antagonist is added after CM treatment when PD-L1 levels on MDSCs are already increased.
[0193] like Figure 5A Conditioned medium (CM) from GM-CSF cancer cell lines with or without recombinant GM-CSF (10 ng / mL) and anti-GM-CSFRα antibody (100 μg / mL) (as shown in Table 1) were added to CD14+ monocytes (MDSCs) on day 1. After three days of incubation, MDSC cells were analyzed for expression of PD-L1.
[0194] Table 1.
[0195]
[0196] Consistent with Example 3, adding conditioned medium from a cancer cell line expressing GM-CSF (B; CM) or CM with recombinant GM-CSF (D; CM + GM-CSF) to MDSCs increased PD-L1 expression levels compared to baseline (A; medium only). In addition, when anti-GM-CSFRα antibody was added simultaneously with CM or CM + GM-CSF, respectively, Figure 5A As shown in samples C and E, a decrease in PD-L1 was observed, indicating that the anti-GM-CSFRα antibody blocked the upregulation of PD-L1 on MDSCs.
[0197] Next, the effect of adding anti-GM-CSFRα antibodies after incubation of MDSCs with conditioned media has been established to examine the effect of GM-CSF blockade on PD-L1 expression levels when PD-L1 levels on MDSCs are elevated. In this particular setting, MDSCs were cultured in conditioned media with or without recombinant GM-CSF ( Figure 5B Then, on day 3, anti-GM-CSFRα antibody was added to Figure 5B Samples C and E (48 hours later). The MDSCs in sample A were incubated in culture medium for three days as a control. The phenotypic analysis of MDSCs was performed on day 4. Figure 5B As shown, treatment of MDSCs with anti-GM-CSFRα antibodies inhibited the expression level of PD-L1 on MDSCs after culturing MDSCs with conditioned medium from cancer cell lines expressing GM-CSF (samples C and E). Notably, after only 24 hours of treatment with anti-GM-CSFRα antibodies, PD-L1 expression in samples C and E was reduced compared to samples B and D, respectively.
[0198] Example 5. Anti-GM-CSFRα Antibodies Reduce MDSC-Mediated T Cell Suppression
[0199] The studies in this example further demonstrate that GM-CSF antagonists can inhibit the suppressive potential of myeloid cell populations on T cell proliferation.
[0200] In this particular experiment, monocytes treated with conditioned medium from cancer cell lines expressing GM-CSF were used for T cell proliferation assays. Briefly, monocytes were cultured in conditioned medium (CM) from cancer cell lines expressing GM-CSF for three days (CM-treated monocytes). T cells (1×10 5 cells). Then, in Figure 6Stimulated T cells were co-cultured with CM-treated monocytes (at a ratio of 2:1 monocytes: T cells) in a mixed lymphocyte reaction (MLR) shown in the presence or absence of supplemented human recombinant GM-CSF (10 ng / mL) and / or anti-GM-CSFRα antibody (100 μg / mL). Stimulated T cells in IMDM culture medium were used as controls together with healthy monocytes. T cells were expanded for 5 days, collected and stained for CD4 and CD8, which are markers of helper T and cytotoxic T cells. Cell proliferation was measured by flow cytometry and evaluated by CFSE dilution.
[0201] Figure 6 Results of T cell proliferation assays are shown as a percentage of proliferating cells (left panel) and as a percentage of the maximum (MFI) by flow cytometry (signal detection of CFSE dilution in CD4+ or CD8+ cells) (right panel). Figure 6 As shown in , CM-treated monocytes suppressed T cell proliferation compared to controls, and addition of recombinant GM-CSF further suppressed T cell proliferation. Treatment with anti-GM-CSFRα antibody (Ab) reduced MDSC-mediated T cell suppression.
[0202] Equivalent solution
[0203] Those skilled in the art will recognize or be able to determine many equivalents to the specific embodiments of the invention described herein using no more than routine experimentation. The scope of the present invention is not intended to be limited to the above description, but as described below:
[0204] 1. A method of treating cancer comprising administering a GM-CSF antagonist to a patient in need of treatment, wherein administration of the GM-CSF antagonist results in suppression of the immunosuppressive activity of myeloid-derived suppressor cells (MDSCs).
[0205] 2. A method of inhibiting the immunosuppressive activity of myeloid-derived suppressor cells (MDSC) in a patient suffering from cancer, comprising administering a GM-CSF antagonist to the patient.
[0206] 3. A method of enhancing an immune response to a cancer treatment comprising administering a GM-CSF antagonist to a patient receiving cancer treatment, wherein the immune response is increased compared to a control.
[0207] 4. A method according to claim 3, wherein the immune response is the percentage of T cell proliferation.
[0208] 5. The method according to item 3 or 4, wherein the control is indicative of the level of immune response in the patient prior to administration of the GM-CSF antagonist.
[0209] 6. The method of item 3 or 4, wherein the control is a reference immune response level in a control patient receiving the cancer treatment in the absence of a GM-CSF antagonist or a reference immune response level based on historical data.
[0210] 7. A method according to any one of items 3 to 6, wherein the cancer treatment is immunotherapy.
[0211] 8. The method according to item 7, wherein administration of the GM-CSF antagonist increases the efficacy of the immunotherapy.
[0212] 9. A method of inhibiting PD-L1 in a cancer patient compared to a control, comprising administering a GM-CSF antagonist to a patient in need of treatment.
[0213] 10. The method of claim 9, wherein administration of the GM-CSF antagonist reduces PD-L1 levels in cancer patients.
[0214] 11. The method according to item 9 or 10, wherein the control is indicative of the level of PD-L1 in the patient before administration of a GM-CSF antagonist.
[0215] 12. The method of item 9 or 10, wherein the control is a reference PD-L1 level in a control patient receiving the cancer treatment in the absence of a GM-CSF antagonist or a reference PD-L1 level based on historical data.
[0216] 13. A method according to any one of items 10 to 12, wherein the PD-L1 level in the patient is reduced by at least 10%, 20%, 30%, 50%, 60%, 70%, 80% or 90% compared to the control.
[0217] 14. A method according to any one of items 9 to 13, wherein the PD-L1 is expressed on MDSCs.
[0218] 15. A method according to claim 14, wherein the PD-L1 is expressed on circulating MDSCs.
[0219] 16. A method according to claim 14, wherein the PD-L1 is expressed on plasma-derived MDSCs.
[0220] 17. The method according to any of the preceding items, wherein the patient has circulating myeloid-derived suppressor cells (MDSCs)
[0221] 18. A method according to any of the preceding items, wherein the patient suffers from a cancer with low levels of infiltrating T cells.
[0222] 19. A method according to any of the preceding items, wherein the patient suffers from a cancer that is refractory to an immune checkpoint inhibitor (ICI).
[0223] 20. The method according to any of the preceding items, wherein the patient suffers from advanced or metastatic cancer.
[0224] 21. The method of any of the preceding items, wherein the patient suffers from a cancer selected from the group consisting of breast cancer, colorectal cancer (CRC), prostate cancer, melanoma, bladder cancer, pancreatic cancer, pancreatic ductal adenocarcinoma, hepatocellular carcinoma, gastric cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinoma, non-Hodgkin lymphoma, cervical cancer, gastrointestinal cancer, genitourinary cancer, brain cancer, mesothelioma, renal cell carcinoma, gynecological cancer, ovarian cancer, endometrial cancer, lung cancer, gastrointestinal cancer, pancreatic cancer, esophageal cancer, hepatocellular carcinoma, cholangiocarcinoma, brain cancer, mesothelioma, malignant melanoma, Merkel Cell Carcinoma, multiple myeloma, acute myelogenous leukemia, chronic myelogenous leukemia, myelodysplastic syndrome, or acute lymphocytic leukemia.
[0225] 22. A method according to any of the preceding items, wherein the patient suffers from a cancer selected from stage IV breast cancer, stage IV colorectal cancer (CRC), prostate cancer or melanoma.
[0226] 23. The method according to any of the preceding items, wherein the method further comprises administering at least one other cancer therapy to the patient.
[0227] 24. The method of claim 23, wherein the at least one other cancer therapy is chemotherapy, MDSC-targeted therapy, immunotherapy, radiotherapy, and combinations thereof.
[0228] 25. The method of item 23 or item 24, wherein the GM-CSF antagonist and the another cancer therapy are administered simultaneously.
[0229] 26. The method of item 23 or item 24, wherein the GM-CSF antagonist and the another cancer therapy are administered sequentially.
[0230] 27. The method according to item 23 or item 24, wherein the patient has been treated with the other cancer therapy prior to administration of the GM-CSF antagonist.
[0231] 28. The method according to item 23 or item 24, wherein the patient has received treatment with the GM-CSF antagonist prior to administration of the other cancer therapy.
[0232] 29. A method according to any one of items 23 to 28, wherein the other cancer therapy is ICI.
[0233] 30. A method according to any one of item 29, wherein the ICI antagonizes the activity of PD-1, CTLA-4, B7, BTLA, HVEM, TIM-3, GAL-9, LAG3, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK1, CHK2 or A2aR.
[0234] 31. A method according to claim 29, wherein the ICI is selected from anti-PD-1 antibodies (optionally pembrolizumab, nivolumab, cemiplimab), anti-PD-L1 antibodies (optionally atezolizumab, avelumab, durvalumab), anti-CTLA-4 antibodies (optionally ipilimumab), anti-PD-L2 antibodies, anti-B7-H3 antibodies, anti-B7-H4 antibodies, anti-BTLA antibodies, anti-HVEM antibodies, anti-TIM-3 antibodies, anti-GAL-9 antibodies, anti-LAG3 antibodies, anti-VISTA antibodies, anti-KIR antibodies, anti-2B4 antibodies, anti-CD160 antibodies, anti-CGEN-15049 antibodies, anti-CHK1 antibodies, anti-CHK2 antibodies, anti-A2aR antibodies, anti-B-7 antibodies, and combinations thereof.
[0235] 32. A method according to claim 29, wherein the ICI is an anti-PD-L1 antibody.
[0236] 33. A method according to any one of items 24 to 32, wherein the method further comprises administering a chemotherapeutic agent to the patient.
[0237] 34. A method according to any one of items 24 to 28, wherein the MDSC-targeted therapy is selected from anti-CFS-1R antibodies, anti-IL-6 antibodies, all-trans retinoic acid, axitinib, entinostat, gemcitabine or phenformin and combinations thereof.
[0238] 35. A method according to any one of items 24 to 28, wherein the immunotherapy is selected from monoclonal antibodies, cytokines, cancer vaccines, T cell engagement therapy, and combinations thereof.
[0239] 36. A method according to claim 35, wherein the monoclonal antibody is selected from anti-CD3 antibody, anti-CD52 antibody, anti-PD1 antibody, anti-PD-L1 antibody, anti-CTLA4 antibody, anti-CD20 antibody, anti-BCMA antibody, bispecific antibody or bispecific T cell engager (BiTE) antibody and combinations thereof.
[0240] 37. A method according to claim 35, wherein the cytokine is selected from IFNa, IFNp, IFNy, IFN, IL-2, IL-7, IL-15, IL-21, IL-11, IL-12, IL-18, hGM-CSF, TNFa or any combination thereof.
[0241] 38. The method according to any of the preceding items, wherein the GM-CSF antagonist is an anti-GM-CSF antibody or a fragment thereof.
[0242] 39. The method according to any one of items 1 to 37, wherein the GM-CSF antagonist is a soluble GM-CSF receptor.
[0243] 40. The method according to any one of items 1 to 37, wherein the GM-CSF antagonist is an anti-GM-CSF receptor antibody or a fragment thereof.
[0244] 41. The method according to item 40, wherein the anti-GM-CSF receptor antibody or fragment thereof is an anti-GM-CSFRα antibody or fragment thereof.
[0245] 42. The method according to item 41, wherein the anti-GM-CSFRα antibody or fragment thereof is a human GM-CSFRα-specific monoclonal antibody α.
[0246] 43. A method according to item 42, wherein the anti-GM-CSFRα antibody is a human or humanized IgG4 antibody.
[0247] 44. The method according to item 42 or 43, wherein the anti-GM-CSFRα antibody is mavrilimumab.
[0248] 45. A method according to any one of items 41 to 44, wherein the anti-GM-CSFRα antibody fragment thereof comprises a light chain complementary determining region 1 (LCDR1) defined by SEQ ID NO:6, a light chain complementary determining region 2 (LCDR2) defined by SEQ ID NO:7, and a light chain complementary determining region 3 (LCDR3) defined by SEQ ID NO:8; and a heavy chain complementary determining region 1 (HCDR1) defined by SEQ ID NO:3, a heavy chain complementary determining region 2 (HCDR2) defined by SEQ ID NO:4, and a heavy chain complementary determining region 3 (HCDR3) defined by SEQ ID NO:5.
[0249] 46. The method according to any of the preceding items, wherein administration of the GM-CSF antagonist and / or the ICI results in a decrease in MDSC levels in the patient compared to a control.
[0250] 47. The method according to any one of the preceding items, wherein administration of the GM-CSF antagonist and / or the ICI results in a reduction in the level of MDSC-mediated immunosuppressive activity in the patient compared to a control.
[0251] 48. The method according to any one of the preceding items, wherein the administration of the GM-CSF antagonist and / or the ICI results in an increase in Lin in the peripheral blood of the patient compared to a control. - CD14 + HLA-DR - The percentage of M-MDSCs was decreased.
[0252] 49. The method according to any one of the preceding items, wherein administration of the GM-CSF antagonist and / or the ICI results in an increase in the percentage of mature MDSC cells in the patient compared to a control.
[0253] 50. The method according to any one of the preceding items, wherein administration of the GM-CSF antagonist and / or the ICI results in a decrease in the level of Treg cells, macrophages and / or neutrophils compared to a control.
[0254] 51. The method according to any of the preceding items, wherein administration of the GM-CSF antagonist and / or the ICI results in a decrease in the level of inhibitory cytokines.
[0255] 52. A method according to claim 51, wherein the inhibitory cytokine is selected from IL-10 and TGFβ.
[0256] 53. The method according to any of the preceding items, wherein administration of the GM-CSF antagonist and / or the ICI results in a reduction in the level of immunosuppressive factors.
[0257] 54. A method according to claim 53, wherein the immunosuppressive factor is selected from arginase 1, inducible nitric oxide synthase (iNOS), peroxynitrite, nitric oxide, reactive oxygen species, tumor-associated macrophages and combinations thereof.
[0258] 55. The method according to any of the preceding items, wherein the administration of the GM-CSF antagonist and / or the ICI results in an increase in CD4 + Increased levels of T effector cells.
[0259] 56. A method according to any one of items 46 to 55, wherein the control is a pre-treatment level or percentage in the patient, or a reference level or percentage based on historical data.
[0260] 57. A pharmaceutical composition for treating cancer, comprising a GM-CSF antagonist and an ICI.
[0261] 58. The pharmaceutical composition according to item 57, wherein the GM-CSF antagonist is an anti-GM-CSF antibody or a fragment thereof.
[0262] 59. A pharmaceutical composition according to item 57, wherein the GM-CSF antagonist is a soluble GM-CSF receptor.
[0263] 60. The pharmaceutical composition according to item 57, wherein the GM-CSF antagonist is an anti-GM-CSF receptor antibody or a fragment thereof.
[0264] 61. The pharmaceutical composition according to item 60, wherein the anti-GM-CSF receptor antibody or fragment thereof is an anti-GM-CSFRα antibody or fragment thereof.
[0265] 62. A pharmaceutical composition according to item 61, wherein the anti-GM-CSFRα antibody or fragment thereof is a human GM-CSFRα-specific monoclonal antibody.
[0266] 63. A pharmaceutical composition according to item 62, wherein the anti-GM-CSFRα antibody is a human or humanized IgG4 antibody.
[0267] 64. The pharmaceutical composition according to items 60 to 63, wherein the anti-GM-CSFRα antibody is Maverickumab.
[0268] 65. A pharmaceutical composition according to any one of items 60 to 63, wherein the anti-GM-CSFRα antibody fragment thereof comprises a light chain complementary determining region 1 (LCDR1) defined by SEQ ID NO:6, a light chain complementary determining region 2 (LCDR2) defined by SEQ ID NO:7, and a light chain complementary determining region 3 (LCDR3) defined by SEQ ID NO:8; and a heavy chain complementary determining region 1 (HCDR1) defined by SEQ ID NO:3, a heavy chain complementary determining region 2 (HCDR2) defined by SEQ ID NO:4, and a heavy chain complementary determining region 3 (HCDR3) defined by SEQ ID NO:5.
[0269] 66. A pharmaceutical composition according to any one of items 57 to 65, wherein the ICI antagonizes the activity of PD-1, CTLA-4, B7, BTLA, HVEM, TIM-3, GAL-9, LAG3, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK1, CHK2, A2aR and a combination thereof.
[0270] 67. A pharmaceutical composition according to any one of items 57 to 63, wherein the ICI is selected from anti-PD-1 antibodies (optionally pembrolizumab, nivolumab, cemiplimab), anti-PD-L1 antibodies (optionally atezolizumab, avelumab, durvalumab), anti-CTLA-4 antibodies (optionally ipilimumab), anti-PD-L2 antibodies, anti-B7-H3 antibodies, anti-B7-H4 antibodies, anti-BTLA antibodies, anti-HVEM antibodies, anti-TIM-3 antibodies, anti-GAL-9 antibodies, anti-LAG3 antibodies, anti-VISTA antibodies, anti-KIR antibodies, anti-2B4 antibodies, anti-CD160 antibodies, anti-CGEN-15049 antibodies, anti-CHK1 antibodies, anti-CHK2 antibodies, anti-A2aR antibodies, anti-B-7 antibodies, and combinations thereof.
[0271] 68. A kit for treating cancer, comprising a pharmaceutical composition comprising a GM-CSF antagonist and a pharmaceutical composition comprising at least another cancer therapy selected from chemotherapy, MDSC-targeted therapy, immunotherapy, radiation therapy, and combinations thereof.
[0272] 69. A kit according to claim 68, wherein the immunotherapy is an ICI selected from the following: anti-PD-1 antibodies (optionally pembrolizumab, nivolumab, cemiplimab), anti-PD-L1 antibodies (optionally atezolizumab, avelumab, durvalumab), anti-CTLA-4 antibodies (optionally ipilimumab), anti-PD-L2 antibodies, anti-B7-H3 antibodies, anti-B7-H4 antibodies, anti-BTLA antibodies, anti-HVEM antibodies, anti-TIM-3 antibodies, anti-GAL-9 antibodies, anti-LAG3 antibodies, anti-VISTA antibodies, anti-KIR antibodies, anti-2B4 antibodies, anti-CD160 antibodies, anti-CGEN-15049 antibodies, anti-CHK1 antibodies, anti-CHK2 antibodies, anti-A2aR antibodies, anti-B-7 antibodies, and combinations thereof.
Claims
1. A method of treating cancer comprising administering a GM-CSF antagonist to a patient in need of treatment, wherein administration of the GM-CSF antagonist results in suppression of the immunosuppressive activity of myeloid-derived suppressor cells (MDSCs).
2. A method of inhibiting the immunosuppressive activity of myeloid-derived suppressor cells (MDSC) in a patient suffering from cancer, comprising administering a GM-CSF antagonist to the patient.
3. A method of enhancing an immune response to a cancer treatment comprising administering a GM-CSF antagonist to a patient receiving cancer treatment, wherein the immune response is increased compared to a control. The method according to claim 3 , wherein the immune response is the percentage of T cell proliferation.
5. The method of claim 3 or 4, wherein the control is indicative of the level of immune response in the patient prior to administration of a GM-CSF antagonist.
6. The method of claim 3 or 4, wherein the control is a reference immune response level in a control patient receiving the cancer treatment in the absence of a GM-CSF antagonist or a reference immune response level based on historical data.
7. The method according to any one of claims 3 to 6, wherein the cancer treatment is immunotherapy.
8. The method of claim 7, wherein administration of the GM-CSF antagonist increases the efficacy of the immunotherapy.
9. A method of inhibiting PD-L1 in a cancer patient compared to a control, comprising administering a GM-CSF antagonist to a patient in need of treatment.
10. The method of claim 9, wherein administration of the GM-CSF antagonist reduces PD-L1 levels in cancer patients.
